Definitive Contract HHSN268201700009C

This is a Cost Plus Fixed Fee contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Pulmokine, Inc. for $1,549,476.97 to conduct IND-enabling studies for a novel inhaled PDGF receptor inhibitor to treat pulmonary arterial hypertension (PAH). The contract has no set-aside designation and was awarded on November 14, 2013, with a completion date of November 14, 2016. Pulmokine, Inc. is the prime contractor, and the contract is for a novel therapy to treat...

This is a federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to the Allegheny Singer Research Institute (AHN Research Institute) to conduct a study exploring the feasibility of using combined modalities to test the safety of the CardioMEMS device in patients with pulmonary arterial hypertension (PAH). The contract, valued at $778,004.14, is for the VASCULAR INTERVENTIONS/INNOVATIONS AND THERAPEUTIC ADVANCES (VITA) program and has a definitive...

<p>This is a firm fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency within the U.S. Department of Health and Human Services, to Boris L. Vaisman. The contract, with a ceiling value of $144,741.44, is for the procurement of professional services and has a total small business set-aside designation. The contract was awarded on February 22, 2017, with a period of performance ending on February 21, 2022.</p>

This is a definitive contract awarded by the Department of Health and Human Services National Institutes of Health National Heart Lung and Blood Institute to Humacyte Global Inc., a for-profit manufacturer, for the &quot;Vascular Interventions/Innovations and Therapeutic Advances (VITA): Bioengineered Grafts for Peripheral Vascular Disease&quot; program. The contract, which has a potential value of $1,570,756.00, is for a base period from November 15, 2013 to November 14, 2014, with a completion...

This is a federal contract awarded by the National Heart Lung and Blood Institute (NHLBI), a civilian agency, to Sujana Biotech, LLC, a self-certified small disadvantaged business. The contract, valued at $783,488.00, is for the development of an anti-thrombotic monoclonal antibody (MAB) with improved safety and efficacy, under the VITA 2 program. The contract is a definitive, firm fixed-price contract with an ultimate completion date of August 14, 2019. The contract was awarded on November...

This is a $97,680 firm fixed price contract awarded by the National Heart Lung and Blood Institute, a civilian agency within the U.S. Department of Health and Human Services. The contract was set aside for small businesses and awarded to Mediomics LLC, a woman-owned small business. The contract is for the development of APTAMER-BASED PINCERS FOR CARDIOVASCULAR BIOMARKERS, which aligns with the National Heart Lung and Blood Institute's mission to support research on heart, lung, and blood...

This is a federal contract award from the National Heart Lung and Blood Institute (NHLBI), a component of the U.S. Department of Health and Human Services (HHS), to a small, woman-owned, minority-owned business named LI, Lina. The contract has a firm fixed price of $319,857.12 and an ultimate completion date of October 14, 2018. The contract was awarded on July 1, 2016 and was not set aside for any specific business type. Without additional details on the original solicitation, the specific...

This is a $239,309.00 firm fixed-price purchase order contract awarded by the National Heart Lung and Blood Institute, part of the U.S. Department of Health and Human Services National Institutes of Health, to Bassi Technologies, LLC, a minority-owned limited liability company. The contract is for LVMG (presumably Lung Vascular and Molecular Genetics) clinical research coordinator services, with a period of performance through February 28, 2023. The contract was not set aside for any specific...

This is a $1,942,337.44 time and materials contract awarded to The ST. John Group, LLC, a Veteran Owned Small Business, by the National Heart Lung and Blood Institute (NHLBI), a component of the National Institutes of Health within the U.S. Department of Health and Human Services. The contract was awarded under the NHLBI Office of Science Policy, Engagement, Education and Communications (OSPEEC) Blanket Purchase Agreement (BPA) Task Area 5 for user-centered research and analytics services. The...

This federal contract was awarded by the National Heart, Lung, and Blood Institute (NHLBI), a civilian agency, to Dupage Medical Technology Inc., a minority-owned, for-profit organization, for the development of an inhibitor of integrin outside-in signaling as a new generation of anti-thrombotic drug. The definitive, cost-plus-fixed-fee contract has a ceiling value of $1,958,172.98 and a completion date of February 14, 2020. The contract was awarded on November 15, 2016 and does not have a...